Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL002 in early Alzheimer's disease
NL-OMON56389Phase 2Completed
- Sponsor
- Alector
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AL002 with Placebo (2 arms). Primary endpoint: Change from baseline in CDR-SB. Started Aug 2021; status: completed.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON56389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56389.